Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63

HOS-116528 · Präparat HOS-094447

62 ENDOTHELIN RECEPTOR ANTAGONISTS Bosentan Not studied. Concomitant use of bosentan When administered concomitantly and PREZISTA co-administered with with PREZISTA and low dose low dose ritonavir may increase plasma ritonavir, the patient’s tolerability concentrations of bosentan. of bosentan should be monitored. Bosentan is expected to decrease plasma concentrations of darunavir and/or its pharmacoenhancer. (CYP3A induction) HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS NS3-4A protease inhibitors Elbasvir/grazoprevir PREZISTA with low dose ritonavir may Concomitant use of PREZISTA increase the exposure to grazoprevir. with low dose ritonavir and (CYP3A and OATP1B inhibition) elbasvir/grazoprevir is contraindicated (see section 4.3). Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to boosted PREZISTA may increase the co-administer boosted PREZISTA exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir. (P-gp, BCRP and/or OATP1B1/3 inhibition) HERBAL PRODUCTS St John's Wort Not studied. St John’s Wort is expected PREZISTA co-administered with (Hypericum perforatum) to decrease the plasma concentrations of low dose ritonavir must not be darunavir and ritonavir. used concomitantly with products (CYP450 induction) containing St John’s Wort (Hypericum perforatum) (see section 4.3). If a patient is already taking St John’s Wort, stop St John’s Wort and if possible check viral levels. Darunavir exposure (and also ritonavir exposure) may increase on stopping St John’s Wort. The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s Wort. HMG CO-A REDUCTASE INHIBITORS Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of Simvastatin are expected to have markedly increased lovastatin or simvastatin may plasma concentrations when cause myopathy, including co-administered with rhabdomyolysis. Concomitant use PREZISTAco-administered with low of PREZISTA co-administered dose ritonavir. with low dose ritonavir with (CYP3A inhibition) lovastatin and simvastatin is therefore contraindicated (see section 4.3). Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of 10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and PREZISTA atorvastatin Cmax ↑ ≈2 fold co-administered with low dose # darunavir/ritonavir ritonavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily. A gradual dose increase of atorvastatin may be tailored to the clinical response. Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin 40 mg single dose pravastatin Cmin ND and PREZISTA co-administered pravastatin Cmax ↑ 63% with low dose ritonavir is required, ¶ an up to five-fold increase was seen in a it is recommended to start with the limited subset of subjects lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)